Collaborations & Alliances

Merck Enters $280M Cancer Collaboration with Complix

Complix to receive upfront fees, research funding, and milestone payments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Complix, a biopharmaceutical company developing a pipeline of protein therapeutics called Alphabodies for the treatment of cancer and severe autoimmune diseases, has entered a strategic drug discovery collaboration with Merck through its subsidiary, Merck Sharp & Dohme Corp. (MSD), to develop cell-penetrating alphabodies (CPABs) for the treatment of cancer.  Complix will use its proprietary Alphabody platform to deliver CPABs against up to two intracellular cancer targets. MSD will fund r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters